SCHEMBL5569494

SCHEMBL5569494

Cc1cc(N)ccc1Oc1ccc(C#N)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
USP2 O75604 1/20 0.40
SLC22A12 Q96S37 1/20 0.39
NSD2 O96028 1/20 0.37
NSD3 Q9BZ95 1/20 0.37
EGFR P00533 1/20 0.37
ERBB2 P04626 1/20 0.37
ERBB3 P21860 1/20 0.37
ERBB4 Q15303 1/20 0.37
GAA P10253 1/20 0.36
MPO P05164 1/20 0.36
TPO P07202 1/20 0.36
EPX P11678 1/20 0.36
LPO P22079 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
AR P10275 4/20 0.36
POLB P06746 1/20 0.36
LRRK2 Q5S007 1/20 0.36
ALOX5AP P20292 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215985 0.82 ERBB2 (0.50) KDM4EALDH1A1EGFRERBB2ERBB3
SCHEMBL3370657 0.82 ALOX5AP (0.44) KDM4EALDH1A1USP2GAAAR
SCHEMBL5570386 0.79 EGFR (0.38) KDM4EALDH1A1EGFRERBB2ERBB3
SCHEMBL26018284 0.79 EGFR (0.38) KDM4EALDH1A1EGFRERBB2ERBB3
SCHEMBL24167943 0.79 MCHR1 (0.38) KDM4EALDH1A1EGFRERBB2ERBB3
SCHEMBL20155262 0.79 AR (0.51) KDM4EALDH1A1USP2SMN1; SMN2AR
SCHEMBL18615405 0.79 AR (0.52) ALDH1A1SLC22A12GAASMN1; SMN2AR
SCHEMBL4798392 0.79 ALDH1A1 (0.41) KDM4EALDH1A1USP2EGFRERBB2
SCHEMBL5569420 0.78 KDM4E (0.46) KDM4EALDH1A1SLC22A12EGFRERBB2
SCHEMBL30879456 0.78 KDM4E (0.46) KDM4EALDH1A1SLC22A12EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232607-A1 Quinazoline Derivatives as Erbb Receptor Tyrosine kinases BRADBURY ROBERT H 2007-10-04 US disclosed
EP-1756088-A1 QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES AstraZeneca AB (SE) 2007-02-28 EP disclosed
WO-2005118572-A1 QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES ASTRAZENECA AB (SE) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232607-A1 Quinazoline Derivatives as Erbb Receptor Tyrosine kinases ERBB2, ERBB3, ERBB4 KDM4E 2348/4885ALDH1A1 3782/4885USP2 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.